Savara stock fell 4.66 percent ahead of the November FDA decision
Savara stock (SVRA) dropped 4.66% as investors await an FDA decision on Molbreevi for autoimmune pulmonary alveolar proteinosis, scheduled for November 22, 2026. Despite a Q2 adjusted EPS miss, analysts maintain a "Moderate Buy" consensus with an average target of USD 10.00, significantly above the current price, though one firm recently downgraded the stock to "Sell." The upcoming FDA decision is seen as central to the investment case for Savara.
Savara stock sits 26.39 percent below its 52-week high
Savara stock (SVRA) is trading at EUR 4.59, 26.39 percent below its 52-week high of USD 7.01. The company reported a second-quarter loss of USD 0.16 per share, missing estimates. Analysts have an average 12-month price target of USD 10.00 for the stock, and the next earnings report is scheduled for November 5, 2026.
Savara Inc CCO Braden Parker Withholds 29,323 Shares for RSU Tax Settlement
Savara Inc.'s Chief Commercial Officer, Braden C. Parker, withheld 29,323 shares of common stock on September 24, 2026, to cover tax obligations from the vesting of restricted stock units. These shares were valued at $5.07 each. Following this transaction, Parker directly holds 75,677 shares of Savara common stock.
Form 4 Savara Inc For: 25 September By Investing.com
This article announces the filing of Form 4 by Savara Inc. on September 25, reporting insider transactions. The brief piece provides the company name and filing date, without offering further details on the transactions themselves. It is published by Investing.com, a financial markets news platform.
Savara Awaits FDA Verdict: Will Molbreevi Pass Regulatory Muster?
Savara Inc. (SVRA) is awaiting an FDA decision on its drug Molbreevi for autoimmune pulmonary alveolar proteinosis (aPAP), expected by November 22, 2026. If approved, Molbreevi would be the first specific treatment for aPAP, addressing a significant unmet medical need in this rare lung disease. The full article content is behind a paywall for RTT Biotech Investor and Intelligent Investor subscribers.
Savara Inc (YB4P.DU) Stock Price, News, Quote & History
This Yahoo Finance page provides detailed information for Savara Inc (YB4P.DU), including its stock price, news, quotes, and historical data. The stock is listed on the Dusseldorf exchange and showed a 3.11% decrease as of the reported time. The page also offers related tickers and general market data.
When Can We Expect A Profit From Savara Inc. (NASDAQ:SVRA)?
This article analyzes when Savara Inc. (NASDAQ:SVRA) is expected to become profitable based on analyst forecasts. It examines the company's current financial position, revenue growth, and expenses to project the timeline for achieving positive net income. The analysis provides insights into the key factors influencing Savara's path to profitability.
Will Long-Term IMPALA-2 aPAP Data at ERS 2026 Change Savara's (SVRA) Narrative
Savara Inc. announced that long-term Phase 3 IMPALA-2 trial data for its molgramostim therapy in autoimmune pulmonary alveolar proteinosis (aPAP) has been accepted for presentation at the ERS Congress in September 2026. This data focuses on sustained efficacy, safety, and biomarker changes, reinforcing the clinical story for a drug targeting a rare lung disease with no approved treatments. While these presentations will support the drug's potential, Savara faces financial challenges including rising losses and dilution risk, with the upcoming FDA decision in November 2026 being a key near-term catalyst.
Does Phase 3 IMPALA-2 aPAP Data at ERS 2026 Change The Bull Case For Savara (SVRA)?
Savara Inc. announced that its Phase 3 IMPALA-2 data for molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP) will be presented at the ERS Congress in Barcelona in September 2026, showcasing long-term efficacy, safety, and biomarker findings. While this reinforces the scientific story of molgramostim, the core investment narrative for Savara hinges on the upcoming FDA approval in November 2026, with the company facing risks like regulatory outcomes, lack of revenue, and widening losses. Investors should consider these factors and other valuation perspectives beyond the ERS data.
Savara Loss Widens as Lung Drug Nears FDA Decision
Savara Inc. reported a wider second-quarter loss of $40.2 million, or 16 cents per share, as it expanded its commercial operations in anticipation of a November 22 FDA decision on its rare-disease drug, MOLBREEVI. The company's general and administrative expenses increased significantly due to higher personnel costs and infrastructure building for the potential U.S. market launch. Savara ended the quarter with strong cash reserves and expects decisions on MOLBREEVI from European and U.K. regulators in late 2026 and early 2027, respectively.
Savara presents molgramostim data at ERS Congress in September
Savara Inc. (NASDAQ:SVRA) announced that data from its Phase 3 IMPALA-2 clinical trial for molgramostim will be presented at the ERS Congress in Barcelona from September 5-9, 2026. These presentations will include an oral presentation on long-term efficacy and safety, and two poster presentations on exercise capacity improvements and biomarker levels. Molgramostim is a recombinant human granulocyte-macrophage colony-stimulating factor in development for autoimmune pulmonary alveolar proteinosis, a rare lung disease with no approved pharmacologic treatments.
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026
Savara Inc. will present results from its Phase 3 IMPALA-2 clinical trial for molgramostim inhalation solution in autoimmune pulmonary alveolar proteinosis (aPAP) at the European Respiratory Society (ERS) Congress in September 2026. The presentations will cover long-term efficacy, safety, and improvements in lung function, exercise capacity, and quality of life for patients. The company will also host an industry mini-symposium on aPAP.
Why Savara (SVRA) Is Getting Attention Today
Savara (SVRA) is attracting attention after reporting a net loss of US$40.23 million and filing a US$108.297 million shelf registration, despite its share price showing a 76.9% one-year return. The company's stock trades at a high price-to-book ratio of 9.9x, significantly above industry averages, suggesting investors are paying a premium based on expectations for its rare respiratory disease pipeline, specifically the Phase 3 molgramostim program. However, ongoing losses and the new shelf registration could temper investor sentiment.
Savara Announces New Employment Inducement Grant - August 20, 2026
Savara Inc. announced inducement grants to eight new employees, consisting of options to purchase 74,500 shares and restricted stock units (RSUs) covering 64,500 shares. These awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan, in accordance with NASDAQ Listing Rules, to attract and retain talent. The options have a 10-year term and vest quarterly, while RSUs vest fully on the two-year anniversary of employment, all subject to continued employment.
A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $9 to $11
This article provides an overview of recent analyst ratings for Savara (SVRA.US), highlighting that analysts forecast a price target between $9 and $11. It compiles a consensus based on ratings from Wall Street analysts, offering investors insight into expert opinions on the stock's potential performance.
Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA
Walleye Capital LLC has initiated a new position in Savara Inc. (NASDAQ:SVRA) by acquiring 248,720 shares valued at approximately $1.53 million during the second quarter. Despite mixed analyst sentiment, with a "Moderate Buy" consensus but recent downgrades, institutional investors collectively hold 87.93% of the company. Savara reported a quarterly loss exceeding expectations, and analysts project continued losses for the foreseeable future.
Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen
Wall Street Zen has downgraded Savara (NASDAQ:SVRA) from a "hold" to a "sell" rating, despite a broader analyst consensus of "Moderate Buy" with a $10.14 price target. The company recently reported a quarterly loss of $0.16 per share, missing expectations, and analysts have lowered earnings forecasts through 2030, projecting continued losses before eventual profitability. Institutional investors hold a significant 87.93% stake in the clinical-stage biopharmaceutical company.
HC Wainwright Brokers Lower Earnings Estimates for Savara
HC Wainwright has lowered its Q3 2026 earnings per share estimate for Savara to a loss of $0.16, down from $0.15, and projects full-year losses through 2028. This adjustment follows Savara's Q2 earnings report, where the company missed consensus estimates with a loss of $0.16 per share. Despite these revised estimates, analysts maintain a "Moderate Buy" rating for Savara with an average price target of $10.14, while institutional investors hold a significant 87.93% stake in the clinical-stage biotech firm.
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf
Savara Inc. reported a wider Q2 2026 net loss of US$40.23 million and filed a US$108.30 million shelf registration for potential share dilution, primarily for an ESOP-related offering. Despite this, the company's investment narrative remains closely tied to the upcoming regulatory decisions for its lead therapy, MOLBREEVI, in the U.S. and Europe, which are expected in late 2026 and early 2027. Investors are advised to weigh the dilution risk against the potential impact of these regulatory outcomes.
HC Wainwright Has Pessimistic View of Savara FY2029 Earnings
HC Wainwright has revised its FY2029 EPS forecast for Savara Inc. (NASDAQ:SVRA) down to $0.09 from $0.11, while projecting FY2030 EPS at $0.37. This revision is still notably above the current full-year consensus estimate of a $0.57 loss per share. Savara recently reported a quarterly loss of $0.16 per share, missing analyst consensus, but its shares rose 2.3% to $5.70.
Savara Inc 2Q 2026: Net loss $(40.2M), EPS $(0.16) — 10-Q Summary
Savara Inc reported a net loss of $(40.2M) and an EPS of $(0.16) for Q2 2026, widening its loss compared to the previous year. As a pre-revenue biopharma company, its financial highlights showed increased losses while business highlights focused on regulatory milestones, clinical progress for MOLBREEVI, and commercial readiness for potential product launches in key markets. The company also continues to invest in R&D and manufacturing to support future supply and regulatory approval.
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf
Savara Inc. reported a wider Q2 2026 net loss of US$40.23 million and filed a US$108.30 million shelf registration for common shares, primarily for an ESOP-related offering. Despite the financial losses and potential dilution, the company's investment narrative remains tied to upcoming regulatory decisions for its lead therapy, MOLBREEVI, in the U.S. and Europe, which are expected in late 2026 and early 2027. Investors are weighing the dilution risk against the potential upside from these regulatory outcomes.
SAVARA Q2 EPS USD -0.16
The article reports that Savara (SVRA) announced its Q2 Earnings Per Share (EPS) as USD -0.16. This financial figure indicates the company's profitability during the second quarter.
Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS
Savara (NASDAQ:SVRA) announced its quarterly earnings, reporting a loss of $0.16 per share, which missed the consensus estimate by $0.02. Shares fell by $0.16 to $5.57 during Tuesday trading. The company maintains a "Moderate Buy" consensus rating from analysts, with an average target price of $10.14.
Savara Extends MOLBREEVI Patent Protection to 2041
Savara Inc. has secured patent protection in Europe and Australia for its investigational lung-disease therapy, MOLBREEVI, extending coverage to March 2041. These patents cover the liquid formulation and add to existing protection for the drug-device combination, strengthening the company's intellectual property portfolio in markets without approved alternatives. MOLBREEVI, an orally inhaled GM-CSF therapy, has received Fast Track, Breakthrough Therapy, and Orphan Drug designations from the FDA for autoimmune pulmonary alveolar proteinosis.
Savara Inc. $SVRA Shares Bought by Renaissance Technologies LLC
Renaissance Technologies LLC significantly increased its stake in Savara Inc. (NASDAQ:SVRA) during the first quarter, purchasing an additional 320,572 shares to own a total of 652,672 shares valued at approximately $3.56 million. Other institutional investors also modified their holdings, with hedge funds and institutions collectively owning 87.93% of Savara's outstanding stock. Analysts maintain a "Moderate Buy" rating for Savara, with an average price target of $10.14, despite the company reporting a quarterly loss of $0.15 per share, slightly missing expectations.
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Savara Inc (SVRA), detailing its current earnings forecast score, analyst ratings, and price targets. Eight analysts have given Savara Inc an average price target of $10.25, with a majority recommending a "Buy." The report also includes recent and projected EPS figures for the company.
Savara (SVRA) to Announce Quarterly Earnings on Wednesday
Savara (NASDAQ:SVRA) is scheduled to announce its Q2 2026 earnings before market open on Wednesday, August 12th. Analysts predict a loss of $0.14 per share on revenue of $2.00 million, with the earnings call set for August 11th at 4:00 PM ET. The company's lead candidate, Molgradex, is currently under regulatory review for autoimmune pulmonary alveolar proteinosis.
Savara investors brace for earnings ahead of crucial FDA review By Investing.com
Savara Inc. is set to report second-quarter earnings, with analysts expecting a loss of $0.145 per share. The clinical-stage biotech company is preparing for a crucial FDA decision on its lead drug candidate, molgramostim, for which it has a PDUFA date set for November 22, 2026. Investors are closely watching the company's cash position, burn rate, and progress on commercial infrastructure ahead of the potential approval.
Savara: High-Potential Binary Bet Cruising To PDUFA After A 3 Month Speed Bump (SVRA)
This article revisits Savara Inc. (SVRA), focusing on its APAP BLA filing progress and identifying the upcoming APAP BLA PDUFA as a pivotal near-term catalyst. The author, who previously rated Savara as a "Buy," highlights the company's clinical and regulatory milestones as key investment drivers. The investment thesis centers on SVRA's execution and regulatory pathway for APAP, with a focus on monitoring the launch of MOLBREEVI if approved.
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference
Savara Inc., a clinical-stage biopharmaceutical company specializing in rare respiratory diseases, announced its participation in the 2026 Jefferies Global Healthcare Conference. Members of their management team will host one-on-one meetings and a fireside chat on June 3rd, 2026. A live webcast and replay of the event will be available on the company's corporate website.
Seven Fleet Capital Management LP Grows Stock Holdings in Savara Inc. $SVRA
Seven Fleet Capital Management LP significantly increased its stake in Savara Inc. (NASDAQ:SVRA) by 371.1% in the first quarter, now owning 295,688 shares valued at $1.61 million. This move is part of a broader trend of institutional investment, with such entities collectively holding 87.93% of the company. Despite Savara missing its quarterly earnings estimates, analysts maintain a "Moderate Buy" rating with a consensus price target suggesting significant upside from its current trading price.
Levi & Korsinsky Urges Savara Inc. (SVRA) Shareholders to Act Before Lead Plaintiff Deadline November 7, 2025
Levi & Korsinsky is urging shareholders of Savara Inc. (SVRA) who suffered losses between March 4, 2024, and May 23, 2025, to act before the lead plaintiff deadline of November 7, 2025. A class action lawsuit alleges that Savara Inc. made false and misleading statements regarding the regulatory approval of its drug MOLBREEVI and potential capital needs. Shareholders can visit the firm's website or contact Joseph E. Levi to learn more about their rights to seek recovery.
Savara Announces European and Australian Patent Offices Have Granted Patents for the Liquid Formulation of MOLBREEVI*, Providing Protection in Europe and Australia Until March 2041
Savara Inc. announced that the European and Australian Patent Offices have granted patents for the liquid formulation of MOLBREEVI, providing intellectual property protection until March 2041 in both regions. These patents strengthen Savara's position in ex-US markets for its investigational drug, which is in Phase 3 development for autoimmune pulmonary alveolar proteinosis (PAP). The company is also pursuing similar patent filings in the U.S., including for the drug-device combination.
SVRA|Savara Inc|Price:5.435|Chg%:-0.075
This article provides a comprehensive stock analysis of Savara Inc (SVRA) from TradingKey, highlighting its relatively weak fundamentals but high growth potential and fairly valued status within the Biotechnology & Medical Research industry. Key insights include very high institutional ownership, recent "Buy" ratings from analysts with a target price of $10.94, and an expected upward trend in the medium term despite recent weak market performance. The company specializes in rare respiratory diseases, with its lead program, molgramostim inhalation solution (MOLBREEVI), in Phase III development.
Savara Inc (SVRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Savara Inc (SVRA), focusing on its support and resistance levels, various technical indicators, and moving averages. As of July 28, 2026, the stock's price momentum score is 3.86, and it is trading between a resistance level of $6.12 and a support level of $4.89. The analysis recommends a neutral stance, noting more sell signals from moving averages despite some oversold indicator readings.
Savara Inc (SVRA) Financial Health: Profitability & Balance Sheet Analysis
Savara Inc (SVRA) currently holds a financial score of 5.22, placing it low within the Biotechnology & Medical Research industry (373 out of 386). The analysis indicates weak financial status and low operating efficiency for the company. Key financial components such as cash and cash equivalents, total assets, total liabilities, and free cash flow have not been fully disclosed by the company.
Savara Inc (SVRA) Institutional Confidence
Savara Inc (SVRA) has an institutional shareholding score of 10.00, placing it first among 386 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 16.97% quarter-over-quarter to 104.36%. Key institutional shareholders include New Enterprise Associates (NEA), Bain Capital Life Sciences Investors, LLC, and VR Adviser, LLC.
Savara Inc (SVRA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Savara Inc (SVRA), listing major shareholders and their proportional holdings. It also breaks down shareholding by type, such as investment advisors and hedge funds, and provides a historical view of institutional shareholdings and recent shareholder activity. Additionally, it lists several ETFs that include SVRA in their portfolios.
Savara Inc (SVRA) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides information on Savara Inc (SVRA)'s dividend history and stock splits. It states that Savara Inc has not distributed any dividends over the past 5 years. While it offers a table for dividend dates, no data is currently available.
Savara Inc (SVRA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Savara Inc (SVRA) has an earnings forecast score of 8.75, ranking 63rd in its industry. Analysts have set an average price target of $10.25, with a majority recommending a "Buy" for the stock. The company's recent EPS was -$0.13, beating market expectations of -$0.15, with the next quarter's EPS expected at -$0.14.
Savara, Inc. Revenue Breakdown – NASDAQ:SVRA
This article provides a financial overview of Savara, Inc. (NASDAQ: SVRA) by detailing its revenue breakdown. It lists various financial data points like statements, statistics, dividends, earnings, and segments. The content also mentions the sources of market and reference data used.
Savara Inc (SVRA) Cash Flow
This article provides a detailed cash flow statement for Savara Inc (SVRA), offering both quarterly and annual data for operating, investing, and financing activities. It breaks down various components such as net income from continuing operations, capital expenditures, and net cash flow from common stock issuance. The article also includes a FAQ section defining different types of cash flow and Savara Inc's performance in each category.
Form 4 Savara Inc For: 24 July By Investing.com
This article announces the filing of a Form 4 for Savara Inc. on July 24, as reported by Investing.com. A Form 4 is a document filed with the SEC by company insiders to report changes in their ownership of company stock. The article provides minimal detail beyond this announcement.
Form 4 Savara Inc For: 24 July By Investing.com
This article reports on a Form 4 filing for Savara Inc. dated July 24. A Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a material change in the holdings of company insiders (directors, officers, or beneficial owners of more than 10% of a company's stock). The article itself contains no further details beyond stating the filing occurred and providing the company name and date.
Savara Inc. CFO Robert Lutz Secures 70,000 Stock Options and 35,000 RSUs in Insider Transaction
Savara Inc.'s Chief Financial and Operating Officer, Robert Lutz, recently acquired 70,000 stock options and 35,000 restricted stock units. This insider transaction signals the leadership's confidence in the company's future performance. The acquisition details are provided for investors monitoring insider activities.
Form 4 Savara Inc For: 24 July By Investing.com
This article from Investing.com reports on a Form 4 filing for Savara Inc. dated July 24. It briefly mentions the stock symbol SVRA, which showed a -4.17% change, and includes typical market data and financially related news.
Savara Inc (NASDAQ: SVRA) grants CFO 70,000 options, 35,000 RSUs
Savara Inc. (NASDAQ: SVRA) announced that its Chief Financial & Operating Officer, Robert Matthew Lutz, received equity awards on July 15, 2026. These awards include 35,000 restricted stock units (RSUs) vesting fully on July 15, 2028, and options for 70,000 shares with an exercise price of $5.81, vesting in 16 quarterly installments. Following these transactions, Lutz directly holds 328,977 shares of common stock and 70,000 stock options.
Savara Inc (SVRA) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Savara Inc (SVRA), noting its current valuation score of 7.70, ranking 208 out of 386 in its industry. It highlights the company's P/E ratio of -9.87 and mentions that relevant data for P/B and P/CF ratios have not yet been disclosed. The stock closed at $5.510, down 4.17% on July 24, 2026.
Savara stock gains as Phase 3 data support FDA review of inhaled lung therapy
Savara Inc. stock is gaining traction as the company's inhaled lung therapy for pulmonary alveolar proteinosis approaches FDA review, backed by positive Phase 3 clinical trial data. While the company currently has limited commercial revenue, the potential approval of this lead product could significantly reshape its financial future. Investors are closely monitoring regulatory milestones, as the treatment aims to provide a less invasive alternative to current therapies for the rare lung condition.
